Antibody-directed, effector cell-mediated tumor destruction.

[1]  J. Perentesis,et al.  Targeted therapies for high-risk acute myeloid leukemia. , 2001, Hematology/oncology clinics of North America.

[2]  K. Matthay,et al.  Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  N. Cheung,et al.  Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Jie-Hui Li,et al.  Tumor Immunity in Perforin-Deficient Mice: A Role for CD95 (Fas/APO-1)1 , 2000, The Journal of Immunology.

[5]  E. Thiel,et al.  Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2. , 1999, Leukemia & lymphoma.

[6]  Craig W. Reynolds,et al.  Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma , 1999, Nature Medicine.

[7]  S. Gillies,et al.  Specific Enzyme-Linked Immunosorbent Assays for Quantitation of Antibody-Cytokine Fusion Proteins , 1999, Clinical Diagnostic Laboratory Immunology.

[8]  S. Gillies,et al.  Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. , 1998, Journal of immunology.

[9]  S. Larson,et al.  3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. , 1998, International journal of oncology.

[10]  M. Uttenreuther-Fischer,et al.  Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Witte,et al.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Gillies,et al.  Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. , 1997, Journal of the National Cancer Institute.

[13]  S. Gillies,et al.  Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. , 1997, Cancer research.

[14]  D. Maloney,et al.  IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma , 1997 .

[15]  R. Bechhofer,et al.  Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  K. Matthay,et al.  A Phase I/IB trial of murine monoclonal anti‐GD2 antibody 14.G2a plus interleukin‐2 in children with refractory neuroblastoma , 1997, Cancer.

[17]  M. Dyer,et al.  Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Reisfeld,et al.  Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  B. Storer,et al.  Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[20]  J. Pancook,et al.  T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy , 1996, The Journal of experimental medicine.

[21]  B. Bodey,et al.  Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. , 1996, Anticancer research.

[22]  J. Stephenson.  Reengineered monoclonal antibodies step up to the plate in cancer studies. , 1995, JAMA.

[23]  K. Matsumoto,et al.  Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. , 1995, Hybridoma.

[24]  G. Riethmüller,et al.  Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.

[25]  J. Ihle,et al.  Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. , 1994, Human gene therapy.

[26]  S. Voss,et al.  Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way. , 1994, Blood.

[27]  R. Seeger,et al.  Treatment of Neuroblastoma Patients with Antiganglioside GD2 Antibody plus Interleukin‐2 Induces Antibody‐Dependent Cellular Cytotoxicity Against Neuroblastoma Detected In Vitro , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[28]  S. Gillies,et al.  Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. , 1993, Bioconjugate chemistry.

[29]  S. Gillies,et al.  Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Ledbetter,et al.  Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. , 1990, Blood.

[31]  K. Sugamura,et al.  Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL- 2 binding , 1990, The Journal of experimental medicine.

[32]  R. R. Robinson,et al.  Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. , 1990, Cancer research.

[33]  G. Hale,et al.  The CAMPATH-1 antigen (CDw52). , 1990, Tissue antigens.

[34]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[35]  S. Gillies,et al.  High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. , 1989, Journal of immunological methods.

[36]  J. Sosman,et al.  Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. , 1989, Cancer research.

[37]  T. Kipps,et al.  Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. , 1989, Cancer research.

[38]  K. Mujoo,et al.  Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. , 1987, Cancer research.

[39]  B. Chen,et al.  Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells. , 1986, Journal of immunology.

[40]  B. Flynn,et al.  Transplantation of HLA-haploidentical T-cell-depleted marrow for leukemia: addition of cytosine arabinoside to the pretransplant conditioning prevents rejection. , 1985, Experimental hematology.

[41]  Joe W. Gray,et al.  The Molecular Basis of Cancer , 1985 .

[42]  K. Foon,et al.  Tumor associated antigen (TAA) mimicry and immunotherapy of malignant diseases from anti-idiotypic antibodies to peptide mimics. , 2001, Cancer chemotherapy and biological response modifiers.

[43]  P. Harari,et al.  Monoclonal antibody blockade of the epidermal growth factor receptor in cancer therapy. , 2001, Cancer chemotherapy and biological response modifiers.

[44]  K. Foon,et al.  Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Albertini,et al.  Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant disease. , 1999, Cancer chemotherapy and biological response modifiers.

[46]  J. Becker,et al.  Immunocytokines: a new approach to immunotherapy of melanoma , 1997, Melanoma research.

[47]  S. Gillies,et al.  Recombinant antibody fusion proteins for cancer immunotherapy. , 1996, Current topics in microbiology and immunology.

[48]  M. Schrappe,et al.  A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. , 1995, European journal of cancer.

[49]  D. Czerwinski,et al.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. , 1994, Blood.

[50]  D. Scheinberg,et al.  Monoclonal antibody therapy of cancer. , 1993, Cancer chemotherapy and biological response modifiers.

[51]  W. Grizzle,et al.  Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. , 1992, Human antibodies and hybridomas.

[52]  R. Bechhofer,et al.  Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2. , 1990, Journal of biological response modifiers.

[53]  D. Longo,et al.  Cancer chemotherapy and biological response modifiers annual , 1987 .

[54]  P. Bunn,et al.  Clinical applications of monoclonal antibodies for patients with leukemia and lymphoma. , 1986, Progress in clinical and biological research.

[55]  E. Reinherz,et al.  Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. , 1981, Progress in hematology.

[56]  Jerne Nk.  Towards a network theory of the immune system. , 1974 .